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Background: Role of renal artery stenting (RAS) in patients with atheromatous renovascular disease (ARVD) remains controversial. We evaluated 
the role of RAS in patients with impaired renal function and ARVD.
Methods: Clinical records of 104 patients, who under went RAS of 123 vessels for ARVD and CRI, were reviewed. Data collection included 
procedural success,serum creatinine level at baseline (CRa in mg/dl), 24 hours after the RAS (CRb), and at 1 month (CRc) and 18 months (CRd) 
follow-up.
Results: Mean age was 72 years (range 51-87yrs). At 18 months ( range 15-27 months) the all cause mortality was 9%. Results are shown in 
tabulated form
Conclusion: RAS in ARVD associated CRI confers intermediate term benefits in terms of stabilization of renal function. .
Table 1 : Serum Creatinine (mg/dl)
CRa CRb CRc CRd p Value
Creatinine 2.5 2.5 2.1 2.2 <0.003*
* between CRa and CRc, and CRa and CRd
Table 2:Follow-up Renal Function
Same % Improved % Decline %
Renal Function 53 36 11
Serum Creatinine as compared to baseline
